Loading
Ovid Therapeutics Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by ALEXANDER MARGARET A., was filed 29 Jan 2025.
Ovid Therapeutics Inc.: what insiders have been doing
This page follows insider dealings at Ovid Therapeutics Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. In the past year (22 October 2025 to 22 October 2026), 12 filings came from 9 insiders.
Only sales appear on the open market, 2 sales in all totalling €25k, filed by 2 insiders. One trade stands out by size: a sale of €14k from Alexander Margaret A., disclosed on 2 March 2026.
Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
With 12 filings in twelve months, the company is quieter than the median of 24 filings across the 3,171 companies we follow on the same exchange. Over the whole record (from 2017), the tally stands at 10 purchases and 6 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 7.3 m USD and net income at -17.4 m USD.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
40
Thresholds
n/a
Buy Volume
€5M
10 ops. · all time
Sell Volume
€173,094
6 ops. · all time
Who traded when
BuySaleMargaret A. Alexander1 buy2 sales
Jeffrey A. Rona2 sales
Since the insiders bought
- +122.9%Entry US$0.70 · Close at T+365 US$1.56
- -86.1%Entry US$3.05 · Close at T+365 US$0.43
- +100.7%Entry US$3.05 · Close at T+365 US$6.12
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Ovid Therapeutics Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$6.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.36
Analyst consensus
10 analystsStrong buy
US$4.00Target US$6.00(+154%)US$9.00
Income statement
RevenueUS$7.3M
EBITDA-US$42.2M-581% margin
Net income-US$17.4M-240.1% margin
Valuation
PER (forward)-6.4x
P/Book2.1x
Beta0.23
Balance sheet & cash
Market capUS$460.9M
Total debtUS$13.4M
Free Cash Flow-US$38.3M
Debt / Equity6%
Profitability & ownership
ROE-26.0%
ROA-23.5%
% insiders6.7%
% institutions80.4%
Last declaration on 24 August 2026
Declarations40 total
325,000 shares@ US$2.800.18% mcap68.2% of flowCommon StockSEC144:0001311404-26-000007
150,000 shares@ US$2.800.083% mcap31.8% of flowCommon StockSEC144:0001311404-26-000005
50,000 shares0Common StockSEC:0001779359-26-000004:0
17,578 shares@ US$2.56100.0% of flowCommon StockSEC:0001886431-26-000004:0
8,789 shares@ US$2.56100.0% of flowCommon StockSEC:0001368324-26-000004:0
17,578 shares@ US$2.56100.0% of flowCommon StockSEC:0001202098-26-000004:0
47,333 shares@ US$1.4055.3% of flowCommon StockSEC:0001256153-26-000004:0
68,125 shares0Common StockSEC:0001311404-26-000002:1
11,656 shares@ US$1.4565.4% of flowCommon StockSEC:0002036798-26-000004:0
8,541 shares@ US$1.4583.4% of flowCommon StockSEC:0001311404-26-000002:0
71,000 sharesCommon StockSEC:0001256153-25-000004:0
1,250,000 shares0Common StockSEC:0001395064-25-000172:0
3,902 shares@ US$0.5616.6% of flowCommon StockSEC:0001415889-25-005997:0
5,279 shares@ US$0.5612.9% of flowCommon StockSEC:0001415889-25-005998:0
43,750 shares0Common StockSEC:0001415889-25-005366:0
43,750 shares0Common StockSEC:0001415889-25-005367:0
6,810 shares@ US$0.7321.7% of flowCommon StockSEC:0001415889-25-002230:0
Canonical exit: 27 Apr 2025 (T+90)
18,248 shares@ US$2.7644.7% of flowCommon StockSEC:0001209191-24-005001:0
Canonical exit: 16 Jun 2024 (T+90)
28,125 shares0Common StockSEC:0001209191-24-003972:0
28,125 shares0Common StockSEC:0001209191-24-003966:0
28,125 shares0Common StockSEC:0001209191-24-003970:0
465,116 shares0Common StockSEC:0001415889-24-003721:0
573,275 shares0Common StockSEC:0001209191-23-057640:1
573,275 shares0Common StockSEC:0001209191-23-057640:0
17,344 shares@ US$2.15100.0% of flowCommon StockSEC:0001209191-22-049938:0
25 of 40 declarations
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc. (NASDAQ: OVID) is a United States-based biopharmaceutical company listed on the NASDAQ market and headquartered in New York, United States. Founded in 2014 and operational since that year, Ovid focuses on small-molecule medicines for brain disorders, particularly conditions driven by neuronal hyperexcitability and impaired excitatory/inhibitory balance. The company is best understood as a clinical-stage neuroscience biotech: it has no broad commercial product base, and its valuation is primarily driven by pipeline execution, clinical readouts, regulatory progress, and financing discipline.
Ovid’s current strategy is centered on a differentiated neuroscience platform. Its lead development program, OV329, is a next-generation GABA-aminotransferase inhibitor being developed primarily for drug-resistant epilepsies and related seizure disorders. Management has reported encouraging early clinical data, including favorable safety, tolerability, pharmacokinetic, and pharmacodynamic findings, supporting advancement into later-stage studies. The company has also expanded OV329 into additional seizure-related indications, including tuberous sclerosis complex seizures and infantile spasms, which broadens the commercial opportunity while keeping the development theme focused on high unmet need.
Read moreShow less
A second strategic pillar is the KCC2 portfolio. Ovid is advancing OV4071, an oral direct activator of the KCC2 transporter, as a potential first-in-class approach aimed at restoring inhibitory tone in the brain. The company’s KCC2 thesis is mechanistic and differentiated: rather than simply treating symptoms, it seeks to address a core biological control point in disorders where hyperexcitability and circuit dysfunction are central. Ovid also used OV350, an intravenous KCC2 direct activator, as a human proof-of-concept and target-validation program, providing clinical support for the broader KCC2 franchise.
Competitively, Ovid operates in a crowded but scientifically attractive field that includes larger pharmaceutical companies and specialist neuroscience biotechs. Its relative strengths lie in target differentiation, a focused pipeline, and the potential to build a proprietary franchise around epilepsy, psychosis, and other CNS disorders. Its limitations are those typical of small-cap biotech: dependence on clinical success, regulatory approvals, and access to capital. As such, the stock carries meaningful event risk, but also meaningful upside if proof-of-concept data continue to confirm the platform.
Recent milestones have been important. In 2026, Ovid reported continued pipeline progress, including Phase 1 dosing for OV4071, expansion of OV329 into complementary seizure indications, and new financing that strengthened its runway. The company has also indicated a longer cash runway and multiple anticipated clinical catalysts over the next 18 to 24 months. For investors following U.S. healthcare equities, OVID on NASDAQ offers a focused, high-risk/high-reward exposure to CNS innovation in the United States.
